## Alexandros A Drosos

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3464212/alexandros-a-drosos-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| 35                | 187                | 8           | 12              |
|-------------------|--------------------|-------------|-----------------|
| papers            | citations          | h-index     | g-index         |
| 36<br>ext. papers | 273 ext. citations | 3.8 avg, IF | 4.08<br>L-index |

| #  | Paper   | IF             | Citations |
|----|---|----------------|-----------|
| 35 | Colchicine Against SARS-CoV-2 Infection: What is the Evidence?. <i>Rheumatology and Therapy</i> , <b>2022</b> , 9, 379  | 4.4            | 1         |
| 34 | Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity?. <i>Clinical Rheumatology</i> , <b>2022</b> , 41, 957  | 3.9            | 2         |
| 33 | A Patient with Symmetrical Polyarthritis. The Value of Conventional Radiography for a Correct Diagnosis <i>Rheumatology and Therapy</i> , <b>2022</b> , 1   | 4.4            | O         |
| 32 | State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis <i>Expert Opinion on Pharmacotherapy</i> , <b>2022</b> , 1-9  | 4              |           |
| 31 | TNFIInhibitor biosimilars associated with alopecia areata. Case-based review <i>Rheumatology International</i> , <b>2022</b> , 1  | 3.6            |           |
| 30 | The changing incidence of rheumatoid arthritis over time in north-west Greece: data from a referral centre <i>Scandinavian Journal of Rheumatology</i> , <b>2022</b> , 1-8  | 1.9            | О         |
| 29 | Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis <i>Expert Review of Clinical Immunology</i> , <b>2022</b> , 1-9  | 5.1            | O         |
| 28 | Fibroblastic rheumatism: an uncommon arthritis. A case-based review. <i>Rheumatology International</i> , <b>2021</b> , 1  | 3.6            |           |
| 27 | Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. <i>Rheumatology International</i> , <b>2021</b> , 41, 903-909 | 3.6            | 5         |
| 26 | Methotrexate and interstitial lung disease. Is there a real causative factor?. <i>Rheumatology International</i> , <b>2021</b> , 41, 2045-2046  | 3.6            |           |
| 25 | COVID-19 in patients with gout on colchicine. <i>Rheumatology International</i> , <b>2021</b> , 41, 1503-1507   | 3.6            | 4         |
| 24 | Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Discovery</i> , <b>2021</b> , 16, 227-234  | 6.2            | 2         |
| 23 | Calcified constrictive pericarditis resulting in tamponade in a patient with systemic lupus erythematosus. <i>Rheumatology International</i> , <b>2021</b> , 41, 651-670  | 3.6            | 1         |
| 22 | Occupational mimics of rheumatoid arthritis: hair dye-induced arthritis. <i>Rheumatology International</i> , <b>2021</b> , 41, 795-797  | 3.6            | 1         |
| 21 | Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 2223-2230   | 3.9            | O         |
| 20 | Correspondence on 'Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis'. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,   | 2.4            | 1         |
| 19 | Insulin resistance in patients with rheumatoid arthritis. Rheumatology International, 2021, 41, 1185-118  | 8 <b>6</b> 3.6 | 1         |

| 18 | Pleural effusion in psoriatic arthritis patients: a case series and review of the literature. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 4741-4748   | 3.9             | 2  |
|----|--|-----------------|----|
| 17 | Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2153-2160   | 4               | 2  |
| 16 | Radiological Findings of the Cervical Spine in Rheumatoid Arthritis: What a Rheumatologist Should Know. <i>Current Rheumatology Reports</i> , <b>2020</b> , 22, 19   | 4.9             | 5  |
| 15 | The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. <i>Rheumatology International</i> , <b>2020</b> , 40, 1181-1191  | 3.6             | 17 |
| 14 | Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. <i>Current Rheumatology Reports</i> , <b>2020</b> , 22, 44  | 4.9             | 6  |
| 13 | Treatment strategies are more important than drugs in the management of rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 1363-1368   | 3.9             | 22 |
| 12 | Adalimumab-induced myasthenia gravis: case-based review. Rheumatology International, 2020, 40, 1891  | - <b>3.8</b> 94 | 5  |
| 11 | Neuroinflammatory events after anti-TNFItherapy. Annals of the Rheumatic Diseases, 2020,   | 2.4             | 4  |
| 10 | Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. <i>Rheumatology International</i> , <b>2019</b> , 39, 1331   | -₹341           | 10 |
| 9  | Eight-year survival study of first-line tumour necrosis factor Inhibitors in rheumatoid arthritis: real-world data from a university centre registry. <i>Rheumatology Advances in Practice</i> , <b>2019</b> , 3, rkz007 | 1.1             | 11 |
| 8  | Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center. <i>Rheumatology International</i> , <b>2019</b> , 39, 663-668                                   | 3.6             | 1  |
| 7  | The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210845                                      | 3.7             | 4  |
| 6  | Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 597-602         | 5.3             | 28 |
| 5  | Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,  | 5.1             | 15 |
| 4  | Etanercept biosimilar SB-4. Expert Opinion on Biological Therapy, 2019, 19, 173-179  | 5.4             | 17 |
| 3  | Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. <i>Rheumatology International</i> , <b>2019</b> , 39, 353-357   | 3.6             | 7  |
| 2  | ABP 501 for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2018, 18, 317-3   | 3 <b>3</b> 24   | 12 |
| 1  | A Response to: Letter to the Editor Regarding the Article: <b>C</b> olchicine Against SARS-CoV-2 Infection: What is the Evidence? <i>CRheumatology and Therapy</i> ,   | 4.4             |    |